Benzinga

FEBRUARY 5, 2024

Ltd is a leading Korean biotechnology company established in 2015, headquartered in Seoul, Korea and led by a management team that has a deep understanding of the biotech industry and a proven track record of success. About Mediforum Mediforum Co., For more information, please visit: [link].

Technology 40

Technology Marketability Finance 40

Benzinga

JANUARY 31, 2024

Ltd is a leading Korean biotechnology company established in 2015, headquartered in Seoul, Korea and led by a management team that has a deep understanding of the biotech industry and a proven track record of success. About Mediforum Mediforum Co., For more information, please visit: [link].

Technology 40

Technology Marketability Finance 40

Brian DeChesare

NOVEMBER 1, 2023

They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios). Life Science and Biotech Teams – These are more on the venture capital side, but some large PE firms have internal teams that also do this. Some of these firms might also fall in the “growth equity” category.

Equity 59

Equity Private Equity Firm Start-ups Banking 59

IVSC

JUNE 12, 2023

She has been involved in multiple valuation assignments for a wide range of industries, including pharma, biotech, healthcare, vitamin retail, specialty chemicals, industrial manufacturing, and gaming and hospitality. She is a co-author of the Kroll Valuation Handbook series, now available exclusively online in the Cost of Capital Navigator.

Risk-free Rate 130

Risk-free Rate Intangible Assets Appraisal Business Valuation 130

Benzinga

NOVEMBER 21, 2022

The Company is reporting today that despite current general market and economic conditions, the anticipated transaction and financing process is active and continuing, with all terms and conditions of financing and structure expected within the next 30 days. Full story available on Benzinga.com.

Finance 40

Finance Marketability 40

Benzinga

FEBRUARY 12, 2024

Voting results of the Court Meeting and General Meeting At the Court Meeting, a majority in number of Scheme Shareholders who voted (either in person or by proxy) and who together represented 95.74 At the General Meeting, 98.08 At the General Meeting, 98.08 The resolution was accordingly passed.

Marketability 40

Marketability 40

Brian DeChesare

MARCH 9, 2022

In VC, this is a bit more complicated because there are “Junior Partners” and “General Partners” and sometimes other levels (Managing Partners, Managing Directors, etc.). Since Junior Partners are in between Principals and General Partners, and since we’ve already covered VC Principals , we will focus on General Partners here.

Finance 83

Finance Start-ups Equity Marketability 83

Benzinga

NOVEMBER 22, 2023

The challenging market conditions impacting the biotech sector have presented a differentiated opportunity to support the company as a private entity. We look forward to working with the team to deliver on its next milestones." Syncona will not be entitled to vote at the Court Meeting.

Debt Financing 40

Debt Financing Finance Start-ups Marketability 40

Equidam

NOVEMBER 23, 2021

Generally, we look at investing in 2 broad categories: ‘essentials for living,’ such as clean water, food, education, and renewable energy; and ‘platforms’ that will be instrumental to delivering the goods and services that Africans need. The other sectors to watch are EduTech, CleanTech, e-Commerce, and Biotech.

Start-ups 52

Start-ups Marketability 52

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 billion; and Synthorx’s sale to Sanofi $2.5

Marketability 40

Marketability Technology 40

Equidam

AUGUST 11, 2022

All this theory generally converges into some tried and tested startup practices. Startups raising up to and including Series A that don’t belong in the next niche category are generally forecasting for 3 years. These could be deep tech startups, biotech, pharma, real estate, banking (because it requires authorizations).

Start-ups 86

Start-ups Banking Marketability 86

Brian DeChesare

SEPTEMBER 20, 2023

” Example answer: “ I would avoid anything in the ‘general AI’ space right now because most of these companies are building ‘products’ that should be features, and most of the benefits from this technology will go to the biggest tech companies, not startups. Q: How do you value a biotech startup?

Start-ups 59

Start-ups Equity Marketability Terminal Value 59

Brian DeChesare

MAY 3, 2023

The DDM is a horrible idea for tech/biotech startups and anything else in the “growth” category with unstable or unpredictable cash flows. Even if you pick the right company, though, the DDM is more difficult to set up and use than a standard DCF because it requires more assumptions and knowledge of the company’s capital structure.

Dividends 64

Dividends Terminal Value Enterprise Value Equity 64

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds.

Marketability 40

Marketability Finance Equity Debt Financing 40

Benzinga

APRIL 22, 2024

On Monday, Eli Lilly and Company (NYSE: LLY ) agreed to acquire a manufacturing facility from Nexus Pharmaceuticals. The deal terms were not disclosed.

64

64

Benzinga

DECEMBER 26, 2023

Bristol Myers Squibb & Co (NYSE: BMY ) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB ) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) focused on actinium-based RPTs.

Equity 105

Equity 105

Benzinga

APRIL 11, 2024

Thursday, Century Therapeutics (NASDAQ: IPSC ) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.

Finance 59

Finance 59

Benzinga

APRIL 11, 2024

On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) agreed to acquire Alpine Immune Sciences Inc (NASDAQ: ALPN ) for $65 per share or approximately $4.9 billion in cash. billion before the acquisition.

Equity 59

Equity 59

Benzinga

APRIL 18, 2024

Cardior is a biotech company focusing on heart diseases, in the case at hand cardiac insufficiency or heart failure. Thursday, Germany’s competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH by Danish pharma giant Novo Nordisk A/S (NYSE: NVO ).

52

52

Benzinga

APRIL 18, 2024

Anne Wojcicki , co-founder and chief executive of 23andMe Holding Co (NASDAQ: ME ), is contemplating taking the genetics testing company private. This potential move comes after a tumultuous three years in public markets that witnessed a significant decline in the company’s valuation, once at $6 billion. billion.

Finance 52

Finance Marketability 52

Benzinga

APRIL 10, 2024

Alpine Immune Sciences Inc (NASDAQ: ALPN ) is reportedly considering strategic options, including a potential sale, following interest from potential buyers. The Seattle-based firm is working closely with advisors and evaluating various possibilities, and at least one major pharmaceutical player has expressed interest in an acquisition.

59

59

Benzinga

APRIL 17, 2024

On Wednesday, Vanda Pharmaceuticals Inc. NASDAQ: VNDA ) confirmed that, since March 2024, it had received several unsolicited proposals from Future Pak LLC to acquire all of Vanda’s outstanding shares. The most recent proposal offered $7.25 – $7.75 per share, subject to certain terms and conditions. as of April 16, 2024.

52

52

Benzinga

MARCH 19, 2024

Tuesday, AstraZeneca Plc (NASDAQ: AZN ) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) for $21.00 per share in cash plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. on March 18, 2024.

Marketability 64

Marketability 64

Benzinga

APRIL 11, 2024

Janux Therapeutics Inc (NASDAQ: JANX ) shares are trading higher following Wednesday’s reports suggesting the company is considering a possible sale following interest from larger pharmaceutical firms.

52

52

Benzinga

APRIL 11, 2024

On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) agreed to acquire Alpine Immune Sciences Inc (NASDAQ: ALPN ) for $65 per share or approximately $4.9 billion in cash.

52

52

Benzinga

MARCH 25, 2024

Monday, AbbVie Inc (NYSE: ABBV ) agreed to acquire Landos Biopharma Inc (NASDAQ: LABP ) for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.

45

45

Benzinga

APRIL 3, 2024

ARCA Biopharma Inc (NASDAQ: ABIO ) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in an all-stock transaction. Oruka Therapeutics is a privately held biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis.

52

52

Benzinga

MARCH 6, 2024

Aptorum Group Limited (NASDAQ: APM ) shares are trading higher after the company announced a merger agreement with privately held YOOV Group Holding Ltd. Both companies’ boards have approved the Merger Agreement. YOOV is a business artificial intelligence (AI) and automation platform to optimize various aspects of business operations.

59

59

Benzinga

APRIL 11, 2024

Eliem Therapeutics Inc (NASDAQ: ELYM ) has agreed to acquire Tenet Medicines Inc. , a development-stage private biotechnology company.

Finance 52

Finance 52

Benzinga

MARCH 20, 2024

Wednesday, Roche Holding AG (OTC: RHHBY ) entered into a definitive agreement with Lonza Group Ltd (OTC: LZAGF ) (OTC: LZAGY ). Under the agreement, Lonza will acquire the Genentech manufacturing facility in Vacaville, California, for $1.2 billion in conjunction with a manufacturing agreement and related quality services and warehousing.

52

52

Benzinga

JULY 7, 2023

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff.

Marketability 98

Marketability 98

Benzinga

MARCH 14, 2024

Thursday, AstraZeneca Plc (NASDAQ: AZN ) agreed to acquire Amolyt Pharma , a clinical-stage biotechnology company focused on developing treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05

52

52

Benzinga

MARCH 14, 2024

First Wave BioPharma Inc (NASDAQ: FWBI ) has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a gastrointestinal (GI) pipeline. First Wave BioPharma signed a non-binding term sheet in December to acquire ImmunogenX.

52

52

Benzinga

FEBRUARY 16, 2024

Friday, XOMA Corporation (NASDAQ: XOMA ) agreed to acquire Kinnate Biopharma Inc (NASDAQ: KNTE ) for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share plus a non-transferable contingent value right (CVR).

59

59

Benzinga

DECEMBER 27, 2023

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) is potentially the sole remaining clinical-stage player with a robust supply chain.

Alpha 69

Alpha Equity 69

Benzinga

APRIL 25, 2023

Assertio Holdings Inc (NASDAQ: ASRT ) will acquire Spectrum Pharmaceuticals Inc (NASDAQ: SPPI ) in an all-stock and contingent value rights (CVR) transaction. Under the terms of the agreement, each Spectrum share will be exchanged for a fixed exchange ratio of 0.1783 shares of Assertio common, implying an upfront value of $1.14 per Spectrum share.

98

98

Benzinga

DECEMBER 29, 2023

UnitedHealth Group Incorporated (NYSE: UNH ) disclosed on Friday that it has entered into an agreement to sell its operations in Brazil to a private investor. Upon closing, the company expects to record a charge of approximately $7 billion, which will be excluded from adjusted earnings, the majority of which. Full story available on Benzinga.com

Equity 64

Equity Marketability 64